Anti‐IL17 Secukinumab in hidradenitis suppurativa: A long‐term drug survival analysis

Abstract Real‐world data on the long‐term effectiveness of the anti‐IL17 agent secukinumab in treating moderate‐to‐severe Hidradenitis suppurativa (HS) are lacking. In this study, 24 patients with moderate–severe HS received five weekly subcutaneous injections followed by maintenance doses every 4 weeks. Primary outcomes included HiSCR, IHS4 reduction, and DLQI measures assessed at 12‐week intervals. The median secukinumab drug survival was 16.0 months (range 3–51), with a 56.5% maximal response rate at 6 months and dropout exceeding 40% at 1 year. Baseline disease burden emerged as a key predictor of treatment response, overshadowing factors like sex or BMI. Prior systemic steroid use negatively impacts drug survival. The study underscores the critical 6‐month window for assessing treatment efficacy, emphasizing the importance of initial induction dosing. Additionally, the newly developed scoring system, IHS4‐55, showed analogies to the older HiSCR score in capturing treatment response. In this real‐life scenario, challenges persist in HS management, necessitating innovative therapeutic approaches and predictive markers.